PGR and invasive breast carcinoma: According to the National Comprehensive Cancer Network (NCCN) guideline, patients with invasive breast cancer who are ERα-positive or progesterone receptor (PR)-positive are eligible for tamoxifen, the selective estrogen receptor modulator (SERM) [5].